Announcements
15 March 2024
Dr. Carlotta Franchi Appointed Editor-in-Chief of Pharmacoepidemiology
We are pleased to announce that Dr. Carlotta Franchi has been appointed Editor-in-Chief of Pharmacoepidemiology (ISSN: 2813-0618).
Dr. Carlotta Franchi is the head of the Laboratory of Pharmacoepidemiology and Human Nutrition, at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Milan, Italy) and the Scientific Coordinator of Italian Institute for Planetary Health (Milan, Italy). She obtained a pharmacy degree at the Parma University (Italy) in 2005. Then, she obtained her Ph.D. in clinical and experimental medicine at Milan University, Italy in 2017. Since 2006, Carlotta has published more than 100 papers in peer-reviewed journals, and supervised over 20 University/Master/Ph.D. students. She has been a project leader for several pharmaco-epidemiological and clinical studies in multimorbid and frail older people, aiming to assess the prevalence and the risk factors for polypharmacy, adverse drug reactions, inappropriate drug prescribing and drug–drug interactions. She also has designed and coordinated several clinical trials in order to assess the efficacy of educational interventions aimed to improve drug use appropriateness in several settings.
Since 2008, she has led, in collaboration with her team, the collection of data for older patients admitted to a wide network of Italian internal and geriatric hospital wards (REPOSI register), in order to assess the association between the use of drugs, in particular polypharmacy, and patients’ clinical outcomes and planned several studies on pharmaco- and clinical-epidemiologic questions related to public health topics.
The following is a short Q&A with Dr. Carlotta Franchi, who shared her vision for the journal with us, as well as her views of the research area and open access publishing:
- What appealed to you about the journal that made you want to take the role of its Editor-in-Chief?
There are not many journals dedicated to pharmacoepidemiology. Pharmacoepidemiology was established in 2022 and operates under an open-access model, which is beneficial for attracting more attention to research in this field and promoting its development. I hope to contribute my efforts during this process as well.
- What is your vision for the journal?
I aspire for this journal to provide opportunities for scholars in the field of pharmacoepidemiology, enabling their research to be read and acknowledged. Additionally, I hope the journal will be indexed in databases like PubMed, Scopus, and WoS within the next few years.
- What does the future of this field of research look like?
The future of pharmacoepidemiology research is likely to be influenced by several key trends and developments, such as big data and real-world evidence (RWE), advanced analytical methods (machine learning, artificial intelligence), precision medicine, global collaboration and data sharing, integration of multiple data sources et cetera.
Overall, the future of research in this field is promising, driven by advances in technology, data science, and collaborative research efforts. By harnessing the power of big data and real-world evidence, researchers will continue to make significant contributions to improving drug safety, optimizing treatment outcomes, and advancing public health.
- What do you think of the development of open access in the publishing field?
An increasing number of scholars are embracing the open access publishing model and are willing to publish their research in open access journals. This is a natural and a logical choice, to give greater visibility to one’s own research.
